Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Novo Nordisk A/S — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $35.32, while Novo Nordisk A/S trades at $45.12 (market cap $198.57B). The key difference: Novo Nordisk A/S pays a 4.03% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVDL | NVO | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $63.98 |
52-Week Low | $21.76 | $35.29 |
Market Cap | — | $198.57B |
Enterprise Value | — | $213.37B |
Dividend Yield | — | 4.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.18, down 4.01% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF has delivered 12.66% year-to-date returns through June 8, 2026, outperforming the S&P 500. Recent stock splits on June 25-26, 2026, adjusted the share structure.
The leveraged ETF offers amplified exposure to Nvidia's AI-driven growth but faces risks from daily reset mechanics and tracking divergence. With Nvidia continuing to beat earnings estimates and maintain AI leadership, NVDL provides tactical upside potential, though volatility compression and leverage decay remain significant concerns for long-term holders.
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
